BR112023000763A2 - Composição farmacêutica, método para preparar 177lu-psma i&t, método para tratar um paciente, complexo, método para tratar um indivíduo - Google Patents

Composição farmacêutica, método para preparar 177lu-psma i&t, método para tratar um paciente, complexo, método para tratar um indivíduo

Info

Publication number
BR112023000763A2
BR112023000763A2 BR112023000763A BR112023000763A BR112023000763A2 BR 112023000763 A2 BR112023000763 A2 BR 112023000763A2 BR 112023000763 A BR112023000763 A BR 112023000763A BR 112023000763 A BR112023000763 A BR 112023000763A BR 112023000763 A2 BR112023000763 A2 BR 112023000763A2
Authority
BR
Brazil
Prior art keywords
treatment
psma
patient
preparing
complex
Prior art date
Application number
BR112023000763A
Other languages
English (en)
Inventor
Mccann Joe
Original Assignee
Point Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Point Biopharma Inc filed Critical Point Biopharma Inc
Publication of BR112023000763A2 publication Critical patent/BR112023000763A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

COMPOSIÇÃO FARMACÊUTICA, MÉTODO PARA PREPARAR 177LU-PSMA I&T, MÉTODO PARA TRATAR UM PACIENTE, COMPLEXO, MÉTODO PARA TRATAR UM INDIVÍDUO. É provido o radiofármaco 177Lu-PSMA I&T, inclusive de altas purezas e com vida útil prolongada. Além disso, são providos métodos de síntese de 177Lu-PSMA I&T e composições farmacêuticas e métodos de tratamento que compreendem 177Lu-PSMA I&T.
BR112023000763A 2020-07-13 2021-07-13 Composição farmacêutica, método para preparar 177lu-psma i&t, método para tratar um paciente, complexo, método para tratar um indivíduo BR112023000763A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063051335P 2020-07-13 2020-07-13
US202163143664P 2021-01-29 2021-01-29
PCT/IB2021/000467 WO2022013610A2 (en) 2020-07-13 2021-07-13 Radiopharmaceutical and methods

Publications (1)

Publication Number Publication Date
BR112023000763A2 true BR112023000763A2 (pt) 2023-03-21

Family

ID=79171978

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023000763A BR112023000763A2 (pt) 2020-07-13 2021-07-13 Composição farmacêutica, método para preparar 177lu-psma i&t, método para tratar um paciente, complexo, método para tratar um indivíduo

Country Status (11)

Country Link
US (4) US11491246B2 (pt)
EP (1) EP4178628A2 (pt)
JP (1) JP2023539990A (pt)
KR (1) KR20240004205A (pt)
AU (1) AU2021309907A1 (pt)
BR (1) BR112023000763A2 (pt)
CA (1) CA3185565A1 (pt)
IL (1) IL299760A (pt)
MX (1) MX2023000623A (pt)
TW (1) TW202216205A (pt)
WO (1) WO2022013610A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3185565A1 (en) 2020-07-13 2022-01-20 Joe Mccann Radiopharmaceutical and methods
WO2023164769A1 (en) * 2022-03-02 2023-09-07 Point Biopharma, Inc. Radiopharmaceutical and methods
CN114404618A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其用途
CN114404619A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
WO2023215333A1 (en) * 2022-05-02 2023-11-09 Point Biopharma, Inc. Radiopharmaceutical and methods
CN115015441B (zh) * 2022-07-14 2023-08-18 原子高科股份有限公司 一种测定镥[177Lu]氧奥曲肽注射液中稳定剂含量的方法
WO2024121722A1 (en) 2022-12-05 2024-06-13 Novartis Ag Method of treating prostate cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005001415A2 (en) * 2003-05-23 2005-01-06 Epix Pharmaceuticals, Inc. Optically pure and enriched isomers of chelating ligands and contrast agents
CA2783275A1 (en) 2003-07-24 2005-02-03 Bracco Imaging S.P.A. Stable radiopharmaceutical compositions and methods for their preparation
RS65324B1 (sr) 2013-10-18 2024-04-30 Novartis Ag Obeleženi inhibitori membranskog antigena specifičnog za prostatu (psma), njihova upotreba kao agenasa za snimanje i farmaceutskih agenasa za lečenje karcinoma prostate
US10683272B2 (en) 2014-05-06 2020-06-16 The Johns Hopkins University Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy
WO2018108287A1 (en) 2016-12-15 2018-06-21 The European Atomic Energy Community (Euratom), Represented By The European Commission Treatment of pmsa expressing cancers
US10596278B2 (en) * 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
CN113164631A (zh) 2018-09-21 2021-07-23 恩多塞特公司 治疗癌症的方法
US11129912B1 (en) 2020-07-13 2021-09-28 POINT Biopharma Inc. Radiopharmaceutical and methods
CA3185565A1 (en) 2020-07-13 2022-01-20 Joe Mccann Radiopharmaceutical and methods

Also Published As

Publication number Publication date
MX2023000623A (es) 2023-04-27
KR20240004205A (ko) 2024-01-11
US11491246B2 (en) 2022-11-08
US20220016274A1 (en) 2022-01-20
US20230302163A1 (en) 2023-09-28
JP2023539990A (ja) 2023-09-21
WO2022013610A2 (en) 2022-01-20
US20240108765A1 (en) 2024-04-04
WO2022013610A3 (en) 2022-03-17
EP4178628A2 (en) 2023-05-17
IL299760A (en) 2023-03-01
AU2021309907A1 (en) 2023-03-02
US20220008564A1 (en) 2022-01-13
TW202216205A (zh) 2022-05-01
CA3185565A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
BR112023000763A2 (pt) Composição farmacêutica, método para preparar 177lu-psma i&t, método para tratar um paciente, complexo, método para tratar um indivíduo
CO2021017504A2 (es) Derivados de benzisoxazol sulfonamida
BR112021020637A2 (pt) Derivados de tetra-hidro-1h-ciclopenta[cd]indeno como inibidores de fator -2(alfa) induzível por hipóxia
CL2019003049A1 (es) Compuestos de heteroarilo bicíclicos 6-6 fusionados y su uso como inhibidores de lats.
CL2004000647A1 (es) Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am
PE20131304A1 (es) Heteroarilos y sus usos
UY29360A1 (es) Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones.
UY31063A1 (es) Derivados de n-[6-amino-5-aril-piridin -2-il]-carboxamida, composiciones conteniéndolos, procedimientos de preparación, itermedios utilizados en la preparación y aplicaciones.
CO2019002517A2 (es) Inhibidores de dopamina–β–hidroxilasa
CL2017002354A1 (es) Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
BR112022012385A2 (pt) Método de preparação e aplicação de composto de agente de degradação de proteínas
BR112017006425B8 (pt) Compostos derivados de isoxazol, seus usos, inibidores de isocitrato desidrogenase 1 mutante e da produção de d-2 hidroxiglutamato, agente antitumoral e composição farmacêutica compreendendo os mesmos
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
CL2023000921A1 (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead
BR112022000782A2 (pt) Composto, composição farmacêutica, processo para preparar um composto, composto intermediário, e, uso de um composto, ou de um sal farmaceuticamente aceitável ou solvato do mesmo, ou de uma composição farmacêutica
BR112022017398A2 (pt) Hidrato cristalino de um composto inibidor de jak
AR086987A1 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
MX2020013729A (es) Compuestos de cianotriazol y usos de los mismos.
ZA202309924B (en) Amarouciaxanthin a esters and uses thereof
CO2023012342A2 (es) Inhibidores de enzimas
ECSP23070418A (es) Moduladores de sting (estimulador de genes de interferón)
CL2020001461A1 (es) Inhibidores de dopamina–b–hidroxilasa.
BR112022004032A2 (pt) Composições probióticas mixotróficas e usos das mesmas no tratamento de distensão abdominal